749723
Last Update Posted: 2018-07-20
Recruiting has ended
All Genders accepted | 3 months-30 Years |
174 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
The purpose of this study is to improve overall survival while maintaining a good quality of life in pediatric patients with refractory or recurrent brain tumors (medulloblastomas, supratentorial PNETs, ependymomas WHO grade II and III). Response to different chemotherapy options (intravenous versus oral chemotherapy, intraventricular chemotherapy) as part of a multimodal therapy will be assessed. Progression-free, overall survival and toxicity will be evaluated additionally.
Parts of the study:
P-HIT-REZ-2005: a trial for the treatment of relapsed PNETs (medulloblastomas,supratentorial PNETs)
E-HIT-REZ-2005: a trial for the treatment of relapsed ependymomas (Phase II-Study with temozolomide)
Phase II-Study: intraventricular therapy with etoposide in neoplastic meningitis in relapsed PNETs and ependymomas with subarachnoid tumor manifestation (window study)
Eligibility
Relevant conditions:
Recurrent Brain Tumors
Supratentorial PNETs
Medulloblastomas
Ependymomas
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov